Publications

DateAuthorsTitlePublicationVolumeIssuePages
2017Prof Lesley Seymour, MD'Correspondence information about the author Prof Lesley SeymourEmail the author Prof Lesley Seymour, Jan Bogaerts, PhD, Andrea Perrone, MD, Robert Ford, MD, Prof Lawrence H Schwartz, MD, Prof Sumithra Mandrekar, PhD, Nancy U Lin, MD, Saskia Litière, PhD, Prof Janet Dancey, MD, Alice Chen, MD, Prof F Stephen Hodi, MD, Patrick Therasse, MD, Prof Otto S Hoekstra, MD, Lalitha K Shankar, MD, Jedd D Wolchok, MD, Marcus Ballinger, PhD, Caroline Caramella, MD, Prof Elisabeth G E de Vries, MD on behalf of the RECIST working groupiRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology183e143-e152
2016Saskia Litière, Sandra Collette, Elisabeth G. E. de Vries, Lesley Seymour & Jan BogaertsRECIST - learning from the past to build the futureNature Reviews Clinical
2016Lawrence H. Schwartz, Lesley Seymour, Saskia Litière, Robert Ford, Stephen Gwyther, Sumithra Mandrekar, Lalitha Shankar, Jan Bogaerts, Alice Chen, Janet Dancey, Wendy Hayes, F. Stephen Hodi, Otto S. Hoekstra, Erich P. Huang, Nancy Lin, Yan Liu, Patrick Therasse, Jedd D. Wolchok, Elisabeth de VriesRECIST 1.1 - Standardisation and Disease Specific Adaptations: Perspectives from the RECIST Working GroupEuropean Journal of Cancer62138-145
2016Lawrence H. Schwartz, Saskia Litière, Elisabeth de Vries, Robert Ford, Stephen Gwyther, Sumithra Mandrekar, Lalitha Shankar, Jan Bogaerts, Alice Chen, Janet Dancey, Wendy Hayes, F. Stephen Hodi, Otto S. Hoekstra, Erich P. Huang, Nancy Lin, Yan Liu, Patrick Therasse, Jedd D. Wolchok, Lesley SeymourRECIST 1.1 - Update and Clarification: From the RECIST CommitteeEuropean Journal of Cancer62132-137
2015Ming-Wen An, Yu Han, Jeffrey P. Meyers, Jan Bogaerts, Daniel J. Sargent and Sumithra J. MandrekarClinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling MethodsJournal of Clinical Oncology33344048-4057
2015Ming-Wen An, Xinxin Dong, Jeffrey Meyers, Yu Han, Axel Grothey, Jan Bogaerts, Daniel J. Sargent, Sumithra J. MandrekarEvaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall SurvivalJournal of the National Cancer Institute10711
2014Sumithra J. Mandrekar, Ming-Wen An, Jeffrey Meyers, Axel Grothey, Jan Bogaerts and Daniel J. SargentEvaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data WarehouseJournal of Clinical Oncology328841-850
2014Litiere S., De Vriese E.G.E., Seymour L., Sargent D., Shankar L., Bogaerts J.Reply to Verlingue, Koscielny and FerteEuropean Journal of Cancer50162889-2891
2014Liu Y., Litiere S., De Vriese G., Sargent D., Shankar L., Bogaerts J., Seymour L.The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology communityEuropean Journal of Cancer502260-266
2014Mandrekar S.J., An M., Meyers J., Grothey A., Bogaerts J., Sargent D.J. Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data WarehouseJournal of Clinical Oncology328841-852
2014Litiere S., De Vries E., Seymour L., Sargent D., Shankar L., Bogaerts J.The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 databaseEuropean Journal of Cancer501847-1853
2009Schwartz L.H., Bogaerts J., Ford R., Shankar L., Therasse P., Gwyther S., Eisenhauer E.A.Evaluation of lymph nodes with RECIST 1.1European Journal of Cancer452261-267
2009Ford R., Schwartz L., Dancey J., Dodd L.E., Eisenhauer E.A., Gwyther S., Rubinstein L., Sargent D., Shankar L., Therasse P., Verweij J.Lessons learned from independent central reviewEuropean Journal of Cancer452268-274
2009Ratain M.J., Sargent D. J.Optimising the design of phase II oncology trials: The importance of randomisationEuropean Journal of Cancer452275-280
2009Editorial boardEuropean Journal of Cancer452ii
2009Sargent D.J., Rubinstein L., Schwartz L., Dancey J.E., Gatsonis C., Dodd L.E., Shankar L.K.Validation of novel imaging methodologies for use as cancer clinical trial end-pointsEuropean Journal of Cancer452290-299
2009Moskowitz C.S., Jia X., Schwartz L.H., Gönen M.A simulation study to evaluate the impact of the number of lesions measured on response assessmentEuropean Journal of Cancer452300-310
2009Dancey J.E., Dodd L.E., Ford R., Kaplan R., Mooney M., Rubinstein L., Schwartz L.H., Shankar L., Therasse P.Recommendations for the assessment of progression in randomised cancer treatment trialsEuropean Journal of Cancer452281-289
2009Verweij J., Therasse P., Eisenhauer E.Cancer clinical trial outcomes: Any progress in tumour-size assessment?European Journal of Cancer452225-227
2009Bogaerts J., Ford R., Sargent D., Schwartz L.H., Rubinstein L., Lacombe D., Eisenhauer E., Verweij J., Therasse P.Individual patient data analysis to assess modifications to the RECIST criteriaEuropean Journal of Cancer452248-260
2009Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer452228-247
2000Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G.New Guidelines to Evaluate the Response to Treatment in Solid TumorsJournal of the National Cancer Institute923205-216